Revision of Licensing Fee Equivalent for the Distribution of Bioresources Utilizing Gateway® Technology
RIKEN BioResource Research center has entered into a licensing agreement with Thermo Fisher, Inc. (formerly Invitrogen IP Holdings, Inc.) in July 2009 regarding the preservation and distribution of bioresources utilizing Gateway® Technology covered by patents owned by Thermo Fisher, Inc. (Life Technologies Corporation signs license agreement with RIKEN BRC) According to the agreement, for the distribution of Gateway® expression clones containing mammalian cDNA, users are required to bear a licensing fee equivalent amount.
BRC has recently conducted a review prompted by recent exchange rate fluctuations and other factors, and as a result, BRC has decided to revise the licensing fee equivalent amount as follows. We kindly ask for your understanding in this matter.
Effective Fee Revision Date:
For bioreagents requested after April 1, 2024 (Monday) Japan Time, BRC will provide them at the revised fees. For requests made before this date, the current fees will apply.
Amount of Licensing Fee Equivalent:
Current: JPY1,250
Revised: JPY2,090
Please download and read Limited Use Label License: No.19 (GatewayR Cloning Products) [PDF]
(2024.03.14 T.M.)
2024.03.14
